glp 1 gip glucagon triple agonist New strategies for the treatment of obesity and metabolic dysfunctions GLP-1 for Weight Loss and

Phase 1 just cleared

Consequently, other strategies for oral administration have been tested and developed, including (but not limited to) coadministration with enzyme inhibitors, structural modifications [cyclization, PEGylation, fatty acid conjugates of polypeptides (lipidization), fusing therapeutic proteins to cobalamin (vitamin B 12 )], and the use of delivery carriers or absorption enhancers

BCIQ Target Profiles

GLP-1 and ERK1/2 pathway Multiple cellular functions benefit from ERK1/2 activation

Other factors contributing to strong growth in the U.S

The pathological mechanism seems to be based on acute tubular necrosis due to dehydration and volume contraction resulting from severe and progressively worsening gastrointestinal symptoms [155]